New treatment for children with recurrent brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of antiangiogenic therapy using biweekly intravenous bevacizumab combined with five oral medications for children with relapsed medulloblastoma, ependymoma, and ATRT. The approach aims to target both tumor and endothelial cells while minimizing toxicity through a metronomic schedule. The study seeks to provide alternative treatment options for these patients, who currently have limited curative therapies available, with the goal of prolonging survival and maintaining a good quality of life.

Why it matters

Who can join: the full rules

Inclusion criteria for patients

* Stratum I: Relapsed or progressive medulloblastoma - completed
* Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease)
* Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease)
* Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease)
* Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative)
* Histological confirmation at diagnosis or relapse Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (Intensity Data; raw data of methylation array)
* Female or male, aged from 0 to \<20 years (at time of original diagnosis)
* Participants must have normal organ and bone marrow function (ALT \<5x institutional upper limit of normal, creatinine \<1.5x institutional upper limit of normal for age, WBC \>1000/mm3, platelets \> 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol
* Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used
* Written informed consent of patients and / or legal guardian

Exclusion criteria for patients

* VP- or subdural peritoneal shunt dependency (can be included in Stratum V)
* Prior treatment with temozolomide/irinotecan (can be included in Stratum V)
* Active infection, pregnancy or breast feeding
* Treatment for current relapse (surgery may be performed before MEMMAT treatment; patients with sites of disease not irradiated are still eligible for the protocol)
* Known hypersensitivity to any of the drugs in the protocol
* Active peptic ulcer
* Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension
* Anticipation of the need for major elective surgery during the course of the study treatment
* Any disease or condition that contraindicates the use of the study medication/treatment or places the patient at an unacceptable risk of experiencing treatment-related complications
* Non-healing surgical wound
* A bone fracture that has not satisfactorily healed

Where it's running

• Helen DeVos Children's Hospital
  Grand Rapids, Michigan, United States Recruiting
• Dell Children's Medical Group SFC-HEM/ONC
  Austin, Texas, United States Recruiting
• Medical University of Graz
  Graz, Austria Recruiting
• Medical University of Innsbruck
  Innsbruck, Austria Recruiting
• Kepler Universitätsklinikum Med Campus IV
  Linz, Austria Recruiting
• Salzburger Universitätsklinikum
  Salzburg, Austria Recruiting

Study contacts

• Principal investigator: Andreas Peyrl, MD — Medical University of Vienna
• Study coordinator: Andreas Peyrl, MD
• Email: andreas.peyrl@meduniwien.ac.at
• Phone: +43 1 40400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TP53 gene therapy (SGT-53) with nivolumab and focused radiation for children with recurrent brain tumors

  This study tests a TP53 gene therapy called SGT-53 combined with the immune drug nivolumab and focused radiation in children whose brain tumors have come back, grown, or not responded to prior treatment.

  Recruiting Early Phase 1 Children's National Research Institute · Washington D.C., District of Columbia · NCT07017816

• Neuro-navigation-guided focused ultrasound with nivolumab for relapsed or progressive high-grade brain tumors in children

  This study tests whether using focused ultrasound to open the blood-brain barrier and give nivolumab is safe and feasible for kids with relapsed or progressive DMG/DIPG or other high-grade brain tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia · NCT07664176

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• Liothyronine with BIT chemotherapy for relapsed medulloblastoma in kids and young adults

  This study tests Liothyronine (L-T3) with a BIT chemotherapy regimen in children and young adults whose medulloblastoma has come back or progressed after standard treatment.

  Recruiting at 2 sites Phase 1/2 University of California, San Francisco · San Francisco, California and 2 other locations · NCT07346157

• Registry for relapsed or progressive SHH medulloblastoma with U1 mutation

  This registry collects medical records and biological samples from people aged 3–50 with relapsed or progressive SHH medulloblastoma to test for U1 mutations and create a biobank for research.

  Recruiting at 2 sites Baylor College of Medicine · Houston, Texas and 1 other locations · NCT07242963

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.